165728 20260217205612.0 sideral 147129 ART-2024-147129 eng Clusa, Laura Antimicrobial activity and potential of Olive leaf extract as a topical agent to combat Staphylococcus aureus and MRSA strains: an in vitro evaluation 2024 Access copy available to the general public Unrestricted Background: Staphylococcus aureus is one of the most prevalent bacteria in skin and soft tissue infections (SSTIs). Multidrug-resistant strain emergence, particularly methicillin-resistant S. aureus (MRSA), highlights the need for alternative treatments. Objectives: This study investigates the antimicrobial properties of olive leaf extract (OLE) and describes an epidemiological profiling of patients with SSTI who may benefit from it. Methods: OLE was tested in two reference strains, methicillin-susceptible S. aureus (MSSA) ATCC 29213 and MRSA ATCC 700699, and in 126 clinical isolates from patients with SSTIs according to Clinical Laboratory Standards Institute guidelines. Results: The minimum bactericidal concentration (MBC) ranged from 3.12% to 6.25% w/v for MSSA and 1.56% to 3.12% for MRSA. The lethal curve showed a reduction of 6 log10CFU/mL after two hours of incubation. Most of the 126 clinical samples (103 MSSA and 23 MRSA) came from skin lesions, surgical wounds, and ulcers. Over 90% of MSSA strains were resistant to less than five antibiotics, while 82% of MRSA strains were resistant to more than six. Penicillins demonstrated the lowest susceptibility rate (19.8%), whereas linezolid, daptomycin, pristinamycin, trimethoprim–sulfamethoxazole, teicoplanin, vancomycin, and OLE exhibited 100% susceptibility. No growth was observed for all clinical strains with OLE at ≥6.25% w/v. Conclusions: The findings suggest that OLE could become a promising alternative treatment for skin infections, particularly in the context of increasing antibiotic resistance. info:eu-repo/grantAgreement/ES/CIBERObn/CB06-03-1012 info:eu-repo/grantAgreement/ES/DGA/B10-23R info:eu-repo/grantAgreement/ES/DGA/B16-23R info:eu-repo/grantAgreement/ES/DGA/B59-23D info:eu-repo/grantAgreement/ES/MICINN-AEI/PRTR-C17.I1 info:eu-repo/grantAgreement/ES/MCINN/PID2022-136414OB-I00 info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es 4.8 2024 PHARMACOLOGY & PHARMACY 51 / 352 = 0.145 2024 Q1 T1 CHEMISTRY, MEDICINAL 18 / 72 = 0.25 2024 Q1 T1 1.019 2024 Drug Discovery 2024 Q1 Pharmaceutical Science 2024 Q1 Molecular Medicine 2024 Q2 7.7 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Latorre-Millán, Miriam Milagro, Ana María Tristancho-Baró, Alexander Lopez-Calleja, Ana Isabel García-Lechuz, Juan Manuel (orcid)0000-0002-9582-5472 Fortuño, Blanca Villar, Nuno del Asensio, Mario Martín-Belloso, Olga Odriozola-Serrano, Isabel Martínez-Beamonte Roberto Universidad de Zaragoza (orcid)0000-0002-8100-5596 Osada, Jesús Universidad de Zaragoza (orcid)0000-0002-8251-8457 Rezusta, Antonio (orcid)0000-0001-7294-245X Gilaberte, Yolanda Universidad de Zaragoza (orcid)0000-0001-8034-3617 1002 060 Universidad de Zaragoza Dpto. Bioq.Biolog.Mol. Celular Área Bioquímica y Biolog.Mole. 1002 050 Universidad de Zaragoza Dpto. Bioq.Biolog.Mol. Celular Área Biología Celular 1007 183 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Área Dermatología 18, 9 (2024), 1358 [18 pp.] Pharmaceuticals Pharmaceuticals 1424-8247 1601105 http://zaguan.unizar.es/record/165728/files/texto_completo.pdf Versión publicada 2758185 http://zaguan.unizar.es/record/165728/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:165728 articulos driver 2026-02-17-20:49:24 ARTICLE